Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Roche Holding Ltd.    RHO5   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
Latest news on ROCHE HOLDING LTD.
03:05p ROCHE : FDA approves Roche's Hemlibra for haemophilia A with inhibitors
03:04p ROCHE : FDA Approves Genentech's Gazyva for Previously Untreated Advanced Follic..
03:04p ROCHE : FDA Approves Genentech's Hemlibra for Hemophilia A with Inhibitors
03:02p CHUGAI PHARMACEUTICAL : HEMLIBRA Receives the World's First Regulatory Approval ..
02:28p ROCHE : $14,400 Federal Contract Awarded to Roche Diagnostics
09:15a ROCHE : Roches Hemlibra reduces bleeds in haemophilia A patients
07:42a ROCHE : FDA OKs new therapy for some hemophilia patients
11/20 FTSE recoups early losses as cyclicals recover
11/20DJROCHE : Shares Rise on Positive Results From Clinical Trials
11/20 ROCHE : Hemlibra significantly reduced bleeds in phase III study in haemophilia ..
11/20 ROCHE : Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab)..
11/20 ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (atezolizu..
11/20 GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds in ..
11/19 ROCHE : Duluth hires new parks manager
11/18 ROCHE : to Acquire Lab Business Analytics Firm Viewics
11/18 ROCHE : bags new approvals for Hemlibra, Gazyva
11/18 NOVO NORDISK A/S : FDA approves Roche potential haemophilia blockbuster
11/18 ROCHE : Information and promotion products
11/18 ROCHE : First-ever breast cancer patient journey study in sub-Saharan Africa
11/17 ROCHE : FDA Approves First Test for Screening Zika Virus in Blood Donations
11/17 ROCHE : FDA approves Roche's Hemlibra (emicizumab-kxwh) for haemophilia A with i..
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/17 ROCHE : to acquire Viewics, Inc. to provide data-driven lab business analytics a..
11/17 ROCHE : FDA approves Roche’s Gazyva for previously untreated advanced foll..
11/17 ROCHE : Pioneers Study on Hurdles of Breast Cancer Care in Nigeria, Other Countr..
11/16 CHUGAI PHARMACEUTICAL : ALK Inhibitor "Alecensa®" Approved for the Treatment of ..
11/16 ROCHE : FDA OKs new therapy for some hemophilia patients
11/16 ROCHE : Diagnostic Reagents
11/16 ROCHE : FDA Approves Genentech’s Gazyva for Previously Untreated Advanced ..
11/16 ROCHE : FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A ..
11/16 ROCHE : ADDING MULTIMEDIA FDA Approves Genentech’s HEMLIBRA (emicizumab-kx..
11/16 Marketing and Manufacturing Right Transfer of 13 Long-Term Listed Products fr..
11/16 CHUGAI PHARMACEUTICAL : Concerning Today's Certain Media Report
11/15 ROCHE : Appoints bezerra as roche pharma india md
11/14 CHUGAI PHARMACEUTICAL : ALK Inhibitor 'Alecensa' Approved for the Treatment of F..
11/14 ROCHE : Invitation to Roche’s live audio webcast and conference call post ..
11/14 ROCHE : Roches MS drug Ocrevus nears European market
11/13 ROCHE : IRIS Registry provides largest specialty clinical database for research
11/13 CHUGAI PHARMACEUTICAL : 'AYA's Life,' a Website for Young Cancer Patients and Th..
11/13 CURIS : Reports Third Quarter 2017 Financial Results
11/11 ROCHE : NHS England, Roche come to agreement on Perjeta
11/11 ROCHE : Lack of financial burden data hinders breast cancer care-Roche
11/10 GLAXOSMITHKLINE : Dr Hal Barron appointed Chief Scientific Officer and President..
11/10DJROCHE : Gains Positive CHMP Opinion for MS Drug
11/10 ROCHE : La Roche College to Partner With Kosciuszko Foundation for Benefit Recep..
11/10 ROCHE : OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of..
11/10 ROCHE : J-- Roche Ventana Stainer Maintenance
11/10 ROCHE : FDA Approves Genentech's Alecensa as First-Line Treatment for People wit..
11/10 ROCHE : FDA approves Roche's Alecensa as first-line treatment for people with sp..
11/10 ROCHE : Genentech - FDA Approves Zelboraf for Erdheim-Chester Disease with BRAF ..
11/09 ROCHE : FDA OKs Roches Zelboraf for rare blood disease
11/09 RECIPHARM PUBL : Interim report January - September 2017
11/08DJROCHE : Glaxo Names Roche Veteran as Research Head
11/08 GSK grabs Roche veteran and Calico scientist Barron as new R&D head
11/08 LOXO ONCOLOGY : Announces Third Quarter 2017 Financial Results
11/08 CHUGAI PHARMACEUTICAL : Eldecalcitol an Active Vitamin D3 Derivative Increases B..
11/08 ROCHE : Launches Decision Support Software for Oncology Care
11/07 ROCHE : FDA approves Roche's Alecensa (alectinib) as first-line treatment for pe..
11/07 ROCHE : FDA approves Roche’s Alecensa (alectinib) as first-line treatment ..
11/06 ROCHE : FDA Approves Genentech’s Alecensa (Alectinib) as First-Line Treatm..
11/06 ROCHE : FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRA..
11/06 ROCHE : committed to develop KSA clinical research capabilities
11/06 ROCHE : Cranbrook Schools selects new director of schools
11/04 Rheumatoid Arthritis (Ra) Drugs Market 2017-2027
11/04 Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease
11/03 ROCHE : La Roche AITP Receives Student Chapter Outstanding Performance Award
11/03 PACIFIC BIOSCIENCES OF CALIFORNIA : Appoints Kathy Ordoez as Chief Commercial Of..
11/03 ROCHE : First major treatment advance in bladder cancer in three decades reimbur..
11/03 ROCHE : Pharmaceutical company gives free access to drug after clash with Greek ..
11/02 ROCHE : Printed books
11/02 ROCHE : Secondary school construction work
11/02 HALOZYME THERAPEUTICS : First Gastric Cancer Patient Dosed In Clinical Trial Col..
11/02 CHUGAI PHARMACEUTICAL : Head of Science and Strategy to Speak at Medtech & Pharm..
11/02 FITBIT : One Drop and Fitbit to integrate diabetes and activity data
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2017 53 394 M
EBIT 2017 18 161 M
Net income 2017 11 138 M
Debt 2017 10 106 M
Yield 2017 3,53%
P/E ratio 2017 18,15
P/E ratio 2018 16,67
EV / Sales 2017 4,15x
EV / Sales 2018 3,91x
Capitalization 211 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | RHO5 | CH0012032048 | 4-Traders
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 271  CHF
Spread / Average Target 11%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-8.95%212 913
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550